# Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448

> **NCT01132404** · PHASE1,PHASE2 · TERMINATED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Prostate Cancer
- Prostatic Neoplasms

## Interventions

- **DRUG:** Leuprorelin
- **DRUG:** TAK-448

## Key facts

- **NCT ID:** NCT01132404
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11
- **Primary completion:** 2011-09
- **Final completion:** 2011-12
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Developing new formulation of study drug. New study to open next year under a new protocol.
- **Last updated:** 2012-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01132404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01132404, "Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01132404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*